Enlivex Therapeutics Future Growth
Future criteria checks 0/6
Enlivex Therapeutics's earnings are forecast to decline at 22.7% per annum. EPS is expected to grow by 4.5% per annum.
Key information
-22.7%
Earnings growth rate
4.5%
EPS growth rate
| Biotechs earnings growth | 51.2% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -27 | -27 | -27 | 1 |
| 12/31/2025 | N/A | -14 | -14 | -14 | 2 |
| 12/31/2024 | N/A | -13 | -12 | -14 | 2 |
| 6/30/2024 | N/A | -22 | -17 | -17 | N/A |
| 3/31/2024 | N/A | -26 | -22 | -22 | N/A |
| 12/31/2023 | N/A | -29 | -24 | -24 | N/A |
| 9/30/2023 | N/A | -27 | -26 | -23 | N/A |
| 6/30/2023 | N/A | -27 | -28 | -24 | N/A |
| 3/31/2023 | N/A | -30 | -34 | -26 | N/A |
| 12/31/2022 | N/A | -31 | -32 | -24 | N/A |
| 9/30/2022 | N/A | -29 | -32 | -26 | N/A |
| 6/30/2022 | N/A | -26 | -29 | -23 | N/A |
| 3/31/2022 | N/A | -19 | -21 | -18 | N/A |
| 12/31/2021 | N/A | -14 | -19 | -18 | N/A |
| 9/30/2021 | N/A | -16 | -18 | -17 | N/A |
| 6/30/2021 | N/A | -14 | -16 | -15 | N/A |
| 3/31/2021 | N/A | -14 | -15 | -14 | N/A |
| 12/31/2020 | N/A | -12 | -12 | -11 | N/A |
| 9/30/2020 | N/A | -9 | -7 | -7 | N/A |
| 6/30/2020 | N/A | -9 | -7 | -7 | N/A |
| 3/31/2020 | N/A | -8 | -5 | -5 | N/A |
| 12/31/2019 | N/A | -10 | -7 | -7 | N/A |
| 9/30/2019 | N/A | -9 | -7 | -6 | N/A |
| 6/30/2019 | N/A | -7 | -6 | -5 | N/A |
| 3/31/2019 | N/A | -7 | -4 | -3 | N/A |
| 12/31/2018 | N/A | -5 | -4 | -3 | N/A |
| 9/30/2018 | N/A | -4 | -3 | -3 | N/A |
| 12/31/2017 | N/A | -3 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ENLV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ENLV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ENLV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ENLV's revenue is forecast to grow faster than the IL market.
High Growth Revenue: ENLV is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ENLV's Return on Equity is forecast to be high in 3 years time